



XTL Biopharmaceuticals to Present at the JPMorgan Small Cap Conference

NEW YORK, February 13, 2006 - XTL Biopharmaceuticals, Ltd. (LSE: XTL ; NASDAQ: XTLB ; TASE: XTL), a biopharmaceutical company developing drugs against hepatitis, announced today that Ron Bentsur, Chief Executive Officer, will present an overview of the Company at The JPMorgan Small Cap Conference in Philadelphia. Mr. Bentsur's presentation will take place on Thursday, February 16, 2006 at 9:30 a.m. Eastern Time at the Four Seasons Hotel. A live audio webcast of Mr. Bentsur's presentation will be available at <http://equityconferences.jpmorgan.com>. An archived version of the webcast will be available following the conclusion of the live presentation.

Contact:

Ron Bentsur, Chief Executive Officer Tel: +1-212-531-5971

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTLbio") is engaged in the research, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTLbio is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is expected to enter Phase I clinical trial in 1H 2006. XTLbio is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio's hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. In addition, XTL has out-licensed to Cubist Pharmaceuticals an antibody therapeutic against hepatitis B, HepeX-B, which has recently completed a Phase 2b clinical study in transplant patients. XTLbio is publicly traded on the London, NASDAQ, and Tel-Aviv Stock Exchanges (LSE: XTL; NASDAQ: XTLB; TASE: XTL).